Literature DB >> 23151605

Immunogenic cell death and DAMPs in cancer therapy.

Dmitri V Krysko1, Abhishek D Garg, Agnieszka Kaczmarek, Olga Krysko, Patrizia Agostinis, Peter Vandenabeele.   

Abstract

Although it was thought that apoptotic cells, when rapidly phagocytosed, underwent a silent death that did not trigger an immune response, in recent years a new concept of immunogenic cell death (ICD) has emerged. The immunogenic characteristics of ICD are mainly mediated by damage-associated molecular patterns (DAMPs), which include surface-exposed calreticulin (CRT), secreted ATP and released high mobility group protein B1 (HMGB1). Most DAMPs can be recognized by pattern recognition receptors (PRRs). In this Review, we discuss the role of endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in regulating the immunogenicity of dying cancer cells and the effect of therapy-resistant cancer microevolution on ICD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23151605     DOI: 10.1038/nrc3380

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  206 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

2.  Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.

Authors:  Charles S Morrow; Christina Peklak-Scott; Bimjhana Bishwokarma; Timothy E Kute; Pamela K Smitherman; Alan J Townsend
Journal:  Mol Pharmacol       Date:  2006-01-24       Impact factor: 4.436

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

4.  Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.

Authors:  Joanna M Ilvesaro; Melinda A Merrell; Telisha Millender Swain; Jennifer Davidson; Majd Zayzafoon; Kevin W Harris; Katri S Selander
Journal:  Prostate       Date:  2007-05-15       Impact factor: 4.104

5.  NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1.

Authors:  Claudia Semino; Giovanna Angelini; Alessandro Poggi; Anna Rubartelli
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

6.  Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

Authors:  Laurence Zitvogel; Oliver Kepp; Laura Senovilla; Laurie Menger; Nathalie Chaput; Guido Kroemer
Journal:  Clin Cancer Res       Date:  2010-04-26       Impact factor: 12.531

7.  The extracellular release of HMGB1 during apoptotic cell death.

Authors:  Charles W Bell; Weiwen Jiang; Charles F Reich; David S Pisetsky
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-19       Impact factor: 4.249

8.  Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.

Authors:  M P Boland; K A Fitzgerald; L A O'Neill
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

9.  Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells.

Authors:  Nico Hendrickx; Cédric Volanti; Ugo Moens; Ole Morten Seternes; Peter de Witte; Jackie R Vandenheede; Jacques Piette; Patrizia Agostinis
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

10.  Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.

Authors:  C-C Chen; L-T Chen; T-C Tsou; W-Y Pan; C-C Kuo; J-F Liu; S-C Yeh; F-Y Tsai; H-P Hsieh; J-Y Chang
Journal:  Br J Cancer       Date:  2007-07-03       Impact factor: 7.640

View more
  598 in total

Review 1.  "Eat me" imaging and therapy.

Authors:  Vaishali Bagalkot; Jeffrey A Deiuliis; Sanjay Rajagopalan; Andrei Maiseyeu
Journal:  Adv Drug Deliv Rev       Date:  2016-01-27       Impact factor: 15.470

2.  Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells.

Authors:  Irena Adkins; Lenka Sadilkova; Nada Hradilova; Jakub Tomala; Marek Kovar; Radek Spisek
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

Review 3.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Authors:  Kobe Reynders; Tim Illidge; Shankar Siva; Joe Y Chang; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2015-03-28       Impact factor: 12.111

4.  Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.

Authors:  Min-Hee Oh; Im-Hong Sun; Liang Zhao; Robert D Leone; Im-Meng Sun; Wei Xu; Samuel L Collins; Ada J Tam; Richard L Blosser; Chirag H Patel; Judson M Englert; Matthew L Arwood; Jiayu Wen; Yee Chan-Li; Lukáš Tenora; Pavel Majer; Rana Rais; Barbara S Slusher; Maureen R Horton; Jonathan D Powell
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 5.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 6.  Post-translational modifications of high mobility group box 1 and cancer.

Authors:  Seidu A Richard; Yuanyuan Jiang; Lu Hong Xiang; Shanshan Zhou; Jia Wang; Zhaoliang Su; Huaxi Xu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 7.  Nutrition, inflammation and cancer.

Authors:  Laurence Zitvogel; Federico Pietrocola; Guido Kroemer
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

8.  Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.

Authors:  Hing-Yuen Yeung; Pui-Chi Lo; Dennis K P Ng; Wing-Ping Fong
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

9.  Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

Authors:  Hong Jiang; Yisel Rivera-Molina; Candelaria Gomez-Manzano; Karen Clise-Dwyer; Laura Bover; Luis M Vence; Ying Yuan; Frederick F Lang; Carlo Toniatti; Mohammad B Hossain; Juan Fueyo
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

Review 10.  Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Authors:  Samuel T Workenhe; Karen L Mossman
Journal:  Mol Ther       Date:  2013-10-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.